Urothelial Cancer

Andrea Necchi, MD, dives into the details of the SunRISe-4 trial findings, implications, and ways that utDNA and ctDNA may operate as biomarkers in MIBC.

The top 5 OncLive TV videos of the week cover insights in lung cancer, bladder cancer, gastrointestinal cancer, and multiple myeloma.

Primo Nery “Lucky” Lara Jr, MD, has built a genitourinary oncology career inspired by optimism, rooted in perseverance, expanded by innovative thinking, and strengthened by a belief in the power of team science.

The FDA approved T-DXd plus pertuzumab in HER2+ breast cancer, subcutaneous amivantamab in EGFR+ NSCLC, and rucaparib in BRCA-mutated mCRPC.

Enfortumab vedotin plus pembrolizumab is the first perioperative regimen without chemotherapy to improve both EFS and OS in cisplatin-eligible MIBC.

The EMA recommended conditional marketing authorization for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive NMIBC with CIS.

Findings from an exploratory analysis of IMvigor011 support the use of serial ctDNA testing to guide atezolizumab use in MIBC.

Cretostimogene grenadenorepvec shows durable activity in BCG-unresponsive papillary-only NMIBC with no progression to MIBC and favorable tolerability.

Gemcitabine intravesical system in BCG-unresponsive, high-risk NMIBC led to high CR rates and low radical cystectomy rates.

Peripheral neuropathy was linked with improved efficacy outcomes after treatment with first-line enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

Those with metachronous NMIBC experienced poorer outcomes with BCG vs those with primary NMIBC.

Novel sustained-release NDV-01 achieved a 92% CR rate in high-risk patients with NMIBC with strong safety, supporting advancement to phase 3 studies.

Health care providers and allied health care professionals found the gemcitabine intravesical system straightforward to use and safe in NMIBC.

Interim data from ADVANCED-2 show 6- and 12-month CR rates of 69.2% and 50%, respectively, with TARA-002 in this patient population.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

In a recent Peer Exchange, bladder cancer experts reviewed the current treatment paradigm for muscle-invasive bladder cancer (MIBC) and discussed updates from ESMO 2025.

The FDA granted fast track designation to AVZO-103 for urothelial cancer previously treated with enfortumab vedotin.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

The FDA approved 5 therapeutic options spanning lung cancer, urothelial cancer, NF1-associated PNs, and AL amyloidosis.

The FDA has approved neoadjuvant/adjuvant enfortumab vedotin plus pembrolizumab for cisplatin-ineligible muscle-invasive bladder cancer.

Findings from the preliminary cohort show 3- and 6-month CR rates of 56% and 62%, respectively, with detalimogene in this patient population.

The FDA clears subcutaneous daratumumab in smoldering myeloma, adds REMS guidelines for pexidartinib in TGCT, and more.